$168 Million is the total value of Birchview Capital, LP's 54 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 112.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXDX | Buy | ACCELERATE DIAGNOSTICS INC | $18,386,000 | +10.6% | 2,213,326 | +0.9% | 10.92% | +13.9% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $4,567,000 | -16.2% | 177,000 | +73.5% | 2.71% | -13.7% |
| ALBO | Buy | ALBIREO PHARMA INC | $3,913,000 | +13.4% | 111,000 | +20.7% | 2.32% | +16.9% |
| CGEM | New | CULLINAN ONCOLOGY INC | $2,505,000 | – | 60,114 | +100.0% | 1.49% | – |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $2,420,000 | -16.8% | 230,000 | +22.3% | 1.44% | -14.3% |
| BLUE | Buy | BLUEBIRD BIO INC | $2,276,000 | -15.2% | 75,500 | +21.8% | 1.35% | -12.6% |
| NKTR | New | NEKTAR THERAPEUTICS | $1,840,000 | – | 92,000 | +100.0% | 1.09% | – |
| PROG | Buy | PROGENITY INC | $1,285,000 | -3.2% | 270,000 | +8.0% | 0.76% | -0.3% |
| SLNO | Buy | SOLENO THERAPEUTICS INC | $1,105,000 | -30.8% | 876,899 | +6.0% | 0.66% | -28.6% |
| ANGN | New | ANGION BIOMEDICA CORP | $1,095,000 | – | 60,615 | +100.0% | 0.65% | – |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $1,028,000 | +80.4% | 40,000 | +33.3% | 0.61% | +86.0% |
| ALKS | New | ALKERMES PLC | $654,000 | – | 35,000 | +100.0% | 0.39% | – |
| LSF | New | LAIRD SUPERFOOD INC | $525,000 | – | 14,000 | +100.0% | 0.31% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $259,000 | – | 10,000 | +100.0% | 0.15% | – |
| ARQT | New | ARCUTIS BIOTHERAPEUTICS INC | $260,000 | – | 9,000 | +100.0% | 0.15% | – |
| TXMD | New | THERAPEUTICSMD INC | $134,000 | – | 100,000 | +100.0% | 0.08% | – |
| CNCE | New | CONCERT PHARMACEUTICALS INC | $100,000 | – | 20,000 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
| 3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.